Xencor Inc. (XNCR) is a cutting-edge biopharmaceutical firm specializing in the discovery and development of engineered monoclonal antibodies for the treatment of cancer, autoimmune disorders, asthma, and numerous other diseases. Established in 1997 and headquartered in Monrovia, California, Xencor Inc. harnesses the potential of technology to create new standards in biotech and healthcare.
Xencor Inc. primarily focuses on XmAb® technology, its proprietary antibody engineering platform. This pioneering technology explores the unique biological properties of antibodies and allows the modification of protein structures for enhanced performance. Xencor's plug-and-play technology significantly helps to diversify the potential applications and allows the creation of proprietary therapeutic antibodies with improved pharmacologic properties.
Xencor Inc. has an impressive portfolio that consists of more than a dozen internally-developed candidates and partnerships with leading global pharmaceutical companies. Its notable alliances include collaborations with Alexion, Novartis, Genentech, Janssen, and Boehringer Ingelheim. These strategic collaborations not only provide revenues through milestone payments but also allow Xencor to access substantial R&D resources and expand its therapeutic horizons.
Concentrating on the development of XmAb bispecific technology, Xencor restructures an antibody's Fc domain that helps engage two different targets simultaneously, providing groundbreaking strategies for fighting diseases. Xencor's lead product candidates utilizing this technology include XmAb5871 and XmAb7195; both have showcased potential results in clinical studies.
Despite having multiple experimental candidates in their pipeline, Xencor retains its global commercial rights, granting the company full control over its promising future products. Xencor is also involved in several early-stage therapies, co-developed through partnering strategies.
The company’s innovative and novel approach has made it a pioneer in the antibody engineering space, and the XmAB technology holds potential in ushering in a new era of antibody therapeutics. Their work has the potential to provide game-changing therapies for patients suffering from multiple severe and life-threatening diseases.
In the rapidly evolving biopharmaceutical landscape, Xencor Inc. stands out with its robust pipeline and proactive engagements in research collaborations. By focusing intently on improving and optimizing the performance of antibodies to treat diverse health conditions, the firm is harnessing and advancing biotechnology to realize its vision of transforming lives through better medicine.
In conclusion, Xencor Inc. (XNCR) is a dynamic and innovative player in the biopharmaceutical industry, keenly focused on pushing boundaries, revolutionizing treatments, and reinventing the future of healthcare. Blending scientific creativity, technological acumen, and industrial collaborations, Xencor is steering the sector towards promising horizons of patient care and therapeutic interventions.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes Xencor Inc. (NASDAQ: XNCR), highlighting a potential mid-term weak bias despite long-term strength. It presents AI-generated trading strategies including long, breakout, and short setups with specific entry, target, and stop-loss levels. The analysis emphasizes a high risk-reward short setup targeting 21.2% downside against 0.3% risk.
Bank of America raised its price target for Xencor (NASDAQ:XNCR) from $20.00 to $26.00, maintaining a "neutral" rating, which implies a potential upside of 4.78%. Other analysts have also issued positive ratings, contributing to a "Moderate Buy" consensus and an average price target of $31.12. Xencor's shares recently rose by 0.4%, and the company's last quarterly results exceeded expectations, reporting a smaller loss per share and higher revenue than estimated.
BofA Global Research has increased its price objective for Xencor, Inc. (XNCR.O) from $20 to $26. This adjustment reflects an updated outlook from the research firm regarding the biotechnology company's valuation. The report was issued by Reuters.
Hsbc Holdings PLC significantly increased its stake in Xencor, Inc. by 114.2% in the second quarter, now holding 125,482 shares valued at $2.08 million. Other hedge funds like BlackRock Inc. and Primecap Management Co. CA also acquired substantial new stakes in the biopharmaceutical company. Analysts currently rate Xencor with a "Moderate Buy" and an average price target of $31.86, following recent price target adjustments and ratings changes.
UBS Asset Management Americas LLC significantly increased its stake in Xencor, Inc. (NASDAQ:XNCR) by 214.9% in the second quarter, acquiring an additional 260,752 shares to bring its total to 382,094 shares valued at $6.15 million. This move comes as Xencor reported better-than-expected quarterly results, with an adjusted loss of $0.29 per share against an estimated $0.80 loss, and revenue growth of 17.4% year-over-year to $51.22 million. Analyst sentiment for Xencor is generally positive, holding a "Moderate Buy" rating with an average price target of $30.71.
The Manufacturers Life Insurance Company has acquired a new stake of 49,696 shares in Xencor, Inc. (NASDAQ:XNCR), valued at approximately $800,000, representing a 0.07% ownership. This move comes as Xencor reported better-than-expected quarterly results with a smaller loss per share and higher revenue than anticipated. Analysts currently maintain a "Moderate Buy" rating for Xencor with an average price target of $30.71.
Seven Fleet Capital Management LP significantly increased its stake in Xencor, Inc. (NASDAQ:XNCR) by 360.4% in the second quarter, bringing its total holding to 368,305 shares valued at $5.93 million. This comes as other institutional investors, including UBS Asset Management and Susquehanna International Group, also boosted their positions in the biopharmaceutical company. Analysts have a "Moderate Buy" consensus rating for Xencor, with a target price of $30.71, following the company's strong quarterly earnings beat where it surpassed both EPS and revenue estimates.
Man Group plc has acquired a new position in Xencor, Inc. (NASDAQ:XNCR), purchasing 58,380 shares valued at approximately $940,000. This move aligns with a generally positive outlook from analysts, who have given Xencor a "Moderate Buy" rating with an average price target of $30.71. The biopharmaceutical company recently reported strong quarterly results, exceeding revenue and earnings per share estimates.
JPMorgan Chase & Co. has raised its price target for Xencor (NASDAQ:XNCR) from $14 to $21, though it maintains a "neutral" rating, indicating a potential 21% downside from the current price of $26.62. Despite this, Xencor holds a "Moderate Buy" consensus rating among analysts with an average target of $30.71. The biopharmaceutical company recently surpassed quarterly expectations, reporting a smaller adjusted loss of $0.29 per share against an anticipated $0.80 loss, and achieving revenue of $51.22 million, a 17.4% increase year-over-year.